Study published in Biomed Pharmacother. on the effects of GRP119 agonist in the treatment of NASH in STAM™ mice
SMC is proud to announce that Dong-A ST Co., Ltd. (KOR) has published the results of their study using our pre-clinical services with the STAM™ mice in Biomed Pharmacother.
Title: GPR119 activation by DA-1241 alleviates hepatic and systemic inflammation in MASH mice through inhibition of NFκB signaling
(Lee SH et al., Biomed Pharmacother., 2023) Article Link ► [Read Article]
[summary]
In the group of STAM™ mice (8-12 weeks old) with advanced NASH pathology treated with DA-1241, a GRP119 agonist, (1) NAFLD activity score was significantly lower and (2) liver fibrosis area tended to decrease compared to the Vehicle-treated group.
GPR119 (G-protein coupled receptor 119) is expressed in the gastrointestinal tract, liver and pancreas and promotes GLP-1 secretion and glucose-responsive insulin secretion by increasing intracellular cAMP levels. The GPR119 agonists have been researched and developed by many pharmaceutical companies as the next generation of anti-diabetic and NASH drugs. However, these have not yet been launched as NASH drugs.
Previously, it has been shown in nonclinical studies that DA-1241 improves hyperglycemia and dyslipidemia, and it is expected to have a potential therapeutic effect on NASH, which is often associated with those metabolic disorders. Furthermore, in this paper, DA-1241 was found to exert its anti-inflammatory effects by inhibiting the transcription of NF-κB in hepatocytes and macrophages via GPR119, suggesting that it has a multi-targeted therapeutic effect on NASH.
Multifunctional pharmacological effects such as this compound, which suppresses metabolic disorders and inflammation, are very important as a therapeutic strategy for the NASH patients with these multiple pathological backgrounds.
If you have a research project focusing on GPR-mediated metabolic diseases or some compounds that have multiple effects on inflammation, fibrosis, or metabolic disorders, you may consider in vivo studies using STAM™ mice.
If you have any interest or questions, please feel free to contact us.
■About STAM™ mice [Click here]